Five of six mTOR inhibitor-naïve patients with TSC1 or TSC2 inactivating alterations achieved confirmed partial responses to single-agent FYARRO Tumor-agnostic registrational trial of FYARRO in mTOR inhibitor-naïve solid tumors with TSC1 or TSC2 inactivating alterations to be initiated by the end of 2021 LOS ANGELES, June 04, 2021 (GLOBE NEWSWIRE) -- ... Read More

LOS ANGELES, May 19, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience (“Aadi”), a privately-held biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, announces the release of an abstract selected for poster presentation at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting being ... Read More

Transaction to create Nasdaq-listed company focused on advancing Aadi Bioscience’s late-stage pipeline for genetically-defined cancers with alterations in mTOR pathway genes Concurrent $155 million PIPE financing is backed by leading life science investors led by Acuta Capital Partners and KVP Capital and including Avoro Capital Advisors; Avoro Ventures; Venrock Healthcare Capital ... Read More

EOC Pharma acquires exclusive development and commercialization rights to ABI-009 in Greater China Aadi will receive an upfront payment, regulatory and sales milestone payments totaling up to $271M plus royalties Aadi Bioscience (Aadi), a biopharmaceutical company focusing on precision therapies for genomically defined cancers and EOC Pharma (EOC), a leading oncology specialty ... Read More

Rolling submission of U.S. FDA New Drug Application initiated Long-term follow-up data released at ASCO 2020 for AMPECT study Independent reviewed ORR of 39% Long-term, durable ongoing responses with half the responders having ongoing response duration of 25.8 months or longer Exploratory analysis in patients with TSC2 mutated tumors show ... Read More

Business Wire article link: Aadi Bioscience Breakthrough Therapy nab-Sirolimus (ABI-009) Preliminary Data Released from the AMPECT Registration Trial in Advanced PEComa   Highlights: Trial meets its Primary Endpoint with 39% ORR (95%CI 22%-58%) in patients with advanced PEComa – a rare sarcoma with no currently approved therapy First prospective clinical study in advanced ... Read More

Business Wire article link: Aadi Bioscience Breakthrough Therapy nab-Sirolimus (ABI-009) Preliminary Data Released from the AMPECT Registration Trial in Advanced PEComa   June, 3 2019, Aadi Bioscience, Inc. (Aadi), Aadi Bioscience, Inc (Aadi), a privately held clinical stage biopharmaceutical company, today released preliminary data on the ongoing nab-sirolimus (ABI-009) registration trial (AMPECT) for Advanced ... Read More

March, 7 2019, Aadi Bioscience, Inc. (Aadi), For the first time in his life, Shanahan “Shanny” Dameral, 19, has a girlfriend. Soon, he’ll be graduating with a high school diploma and looking for his first job on the Kitsap Peninsula. What seems routine for many is a big deal for Dameral and ... Read More

January, 3 2019, Aadi Bioscience, Inc. (Aadi), a clinical stage biopharmaceutical company focused on treating diseases driven by mTOR activation, today announced that its drug ABI-009 (sirolimus albumin-bound nanoparticles for injectable suspension) has received Breakthrough Therapy Designation status from the FDA for the indication of Advanced (metastatic or locally advanced) Malignant ... Read More